Orchestra BioMed (OBIO) said Tuesday the US Food and Drug Administration has given breakthrough device designation for its atrioventricular interval modulation, or AVIM, therapy to manage hypertension.
The designation is for an implantable device, such as a pacemaker, to deliver AVIM therapy in patients with increased 10-year atherosclerotic cardiovascular disease risk, preserved left ventricular systolic function, and uncontrolled hypertension, the company said.
The therapy, which is being evaluated in a pivotal study in collaboration with Medtronic (MDT), is also for people with intolerance to anti-hypertensive drugs, the company added.
As part of its collaboration with Medtronic, Orchestra said Medtronic holds the right of first negotiation to expand their licensing agreement to include global rights to commercialize AVIM therapy.
Shares of Orchestra were down more than 4% in recent trading.
Price: 2.71, Change: -0.13, Percent Change: -4.58
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。